Visomitin eye drops, 5 ml

Composition

>

1 ml of eye drops contains:

Active ingredient:

plastoquinonyldecyltriphenylphosphonium bromide 0.155 mcg,

excipients:

benzalkonium chloride-0.1 mg;

hypromellose-2 mg;

sodium chloride-9 mg;

sodium dihydrogen phosphate-0.81 mg;

sodium hydrophosphate dodecahydrate-1.16 mg;

sodium hydroxide 1 M solution – up to pH 6.3-7.3;

water for injection-up to 1 ml

Pharmacological action

Visomitin has a keratoprotective effect.

Pharmacodynamics

Plastoquinonyldecyltriphenylphosphonium bromide (PDTP) is a plastoquinone derivative that is linked to a triphenylphosphine residue via a linker chain (C10). PDTP in low (nanomolar) concentrations exhibits high antioxidant activity.

It also has a stimulating effect on the process of tear production, epithelialization, and helps to increase the stability of the tear film. According to a clinical study, in patients with age-related cataracts, the drug protects eye tissues from oxidative damage by increasing the antioxidant activity of the tear, improves visual acuity.

Pharmacokinetics

No pharmacokinetic studies have been performed in humans. In preclinical animal studies, the distribution of PDTP in organs and tissues occurred within 48 hours after intravenous and intragastric administration.

It was found that PDTP is present in the highest concentrations in the tissues of the kidneys, liver and heart within 1 h after administration. PDTP undergoes relatively rapid enzymatic cleavage and covalent binding to proteins.

Indications

Dry eye syndrome, age-related cataracts (to slow the progression of the disease, in order to delay surgery).

Use during pregnancy and lactation

Adequate controlled trials in pregnant and breast-feeding women have not been conducted.

It is not recommended to prescribe the drug during pregnancy.

If it is necessary to prescribe during lactation for the duration of treatment, breastfeeding should be discontinued.

Contraindications

• hypersensitivity to the components of the drug;
• acute inflammatory diseases of the eye and its appendages;
• age up to 18 years.

Side effects

Allergic reactions.

From the side of the senses: there may be a short-term burning sensation and pain in the eyes after instillation.

Interaction

If necessary, it can be applied simultaneously with other eye drops.

At the same time, the break between instillations should be at least 5 minutes.

How to take, course of administration and dosage

Topically (into the conjunctival sac).1-2 drops of the drug 3 times a day.

The duration of treatment is determined by the doctor depending on the severity of symptoms.

The use of the drug in the treatment of age-related cataracts should be carried out under the supervision of a doctor, who should regularly monitor the patient’s condition in order to assess the need for surgical intervention, depending on the progression of the disease.

In the clinical study, the drug was administered for 6 months.

Special instructions

Influence on the ability to drive vehicles and mechanisms.

If short-term blurred vision occurs after using the drug, it is not recommended to drive vehicles or engage in activities that require increased concentration of attention until it is restored.

Form of production

Eye drops.

Storage conditions

In a dark place, at a temperature of 2-8 °C

Shelf life

1 year

Active ingredient

Plastoquinonyldecyltriphenylphosphonium bromide

Dosage form

eye drops

Description

For adults as directed by your doctor

Indications

Dry Eye Syndrome, Cataract

Weight

Weight: 19 gr.